Anna M. Johnston

Hobart, TAS, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Underweight BMI Independently Predicts Inferior Survival in DLBCL Treated With R-CHOP: A Lymphoma Registry Study.

Underweight BMI Independently Predicts Inferior Survival in DLBCL Treated With R-CHOP: A Lymphoma Registry Study.

Journal: European journal of haematology

Published: April 14, 2026

Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study.

Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study.

Journal: Haematologica

Published: March 28, 2025

Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review.

Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review.

Journal: Blood advances

Published: October 17, 2024

Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy.

Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy.

Journal: Blood neoplasia

Published: July 08, 2024

Haematological malignancies during pregnancy: a systematic review of necessary services in the Australian context.

Haematological malignancies during pregnancy: a systematic review of necessary services in the Australian context.

Journal: Internal medicine journal

Published: July 07, 2024

Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma.

Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma.

Journal: Haematologica

Published: May 28, 2024

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.

Journal: EBioMedicine

Published: March 24, 2024

Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.

Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.

Journal: Leukemia & lymphoma

Published: February 20, 2024

Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.

Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.

Journal: EJHaem

Published: November 28, 2023

Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era.

Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era.

Journal: Internal medicine journal

Published: November 15, 2023

Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.

Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.

Journal: American journal of hematology

Published: November 13, 2023

Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies.

Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies.

Journal: Blood advances

Published: October 30, 2023

Showing 1-12 of 44

Last Updated: 09/26/2026